Results presented at the EASD 2026 meeting strengthen the existing body of evidence for semaglutide in treating obesity-related heart failure associated with ejection fraction (HF-pEF). Image credit: Shutterstock/[[StockLab]

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.

With a free Clinical Trials Arena profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven clinical trial intelligence
  • Stay up to date with clinical trial news, regulatory updates, and industry trends
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by